Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GRIP1-associated protein 1 (GRIPAP1)
- Target
- GRIPAP1
- Molecular classification
- Scaffold protein, Guanine nucleotide exchange factor (RasGEF), Other
01
Overview
GRIP1-associated protein 1 (GRIPAP1, commonly called GRASP-1) is a neuronal guanine nucleotide exchange factor (RasGEF) and prominent scaffold protein involved in the trafficking, recycling, and synaptic localization of AMPA-type glutamate receptors through direct interaction with GRIP1. It regulates the recycling of AMPA receptors to dendritic membranes, essential for maintaining dendritic spine morphology and synaptic plasticity processes such as long-term potentiation. GRIPAP1 also serves as a signaling hub, participating in the activation of the JNK signaling cascade, and has further regulatory roles through posttranslational modifications. While not a classic drug target, its dysregulation is implicated in neurological disease processes and possibly oncogenic gene fusions in cancer[1][2][8][3].
- Other names
- GRASP-1GRIPAP1KIAA1167GRASP1GRASP-1 C-terminal chainMPMGp800B12492Q3DKFZp434P063030kDa C-terminus form
02
Mechanism of action
Not applicable; no drugs with a known direct mechanism of action for this protein
03
Biological functions
Regulation of AMPA receptor traffickingEndosomal recycling to the neuronal plasma membraneMaintenance of dendritic spine morphologyFacilitation of long-term potentiation and synaptic plasticityActivation of JNK signaling pathway in neuronsSignal transduction
04
Disease associations
Neurodevelopmental/neurodegenerative disorders (as a potential autoantigen in neurological autoimmunity)Associated (via gene fusion) with certain renal cell carcinomasLidocaine allergyAdrenoleukodystrophy
05
Safety considerations
No notable safety concerns as a direct therapeutic target; clinical challenges might include indirect modulation of synaptic plasticity, with theoretical risks if disrupted
06
Interacting drugs
None reported. There are no approved drugs directly targeting GRIP1-associated protein 1; however, its expression can be modulated indirectly by drugs that affect neuronal activity or relevant signaling pathways.
07
Biomarkers
No established biomarkers for efficacy or patient selection. Its expression/activity may correlate with synaptic function or specific neurological disease states, but this is not clinically validated
Beyond the preview
Go deeper on GRIP1-associated protein 1 (GRIPAP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRIP1-associated protein 1 (GRIPAP1).